URGN Stock Analysis: Buy, Sell, or Hold?
URGN - UroGen Pharma Ltd. Ordinary Shares
$39.19
-0.32 (-0.81%)
▼
5d:
+3.81%
30d:
+32.85%
90d:
+93.24%
HOLD
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
21d
Get Alerted When URGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: URGN trades at premium valuation expecting 12.2% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: URGN trades at premium valuation expecting 12.2% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$38.95
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$24.18
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: URGN is currently trading at $39.19, which is considered extended relative to its 30-day fair value range of $28.54 to $37.30. From a valuation perspective, the stock is trading at a premium (Forward PE: 31.9) compared to its historical average (22.6). At these levels, the market is pricing in 12.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, URGN is in a strong uptrend. The price is approaching resistance at $40.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: URGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, URGN is in a strong uptrend. The price is approaching resistance at $40.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: URGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$28.54 -
$37.30
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
49.0%
Protect Your Profits
Holding URGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+5.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Trading above Wall St target ($37.12)
- NEUTRAL: Trading at premium valuation - market expects 12.2% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$28.54 -
$37.30
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$35.82
Resistance Level
$40.35
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.86
Wall Street Target
$37.13
(-5.3%)
Revenue Growth (YoY)
151.6%
Profit Margin
-94.8%
Valuation Premium vs History
+12.2% premium
PE vs Historical
31.9 vs 22.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.2%
(market-implied from PE analysis)
1-Year Target
$43.97
(+12%)
2-Year Target
$49.34
(+26%)
3-Year Target
$55.35
(+41%)
3-Yr Target (if PE normalizes)
(PE: 32→23)
PE COMPRESSION
$39.26
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: July 15, 2026 12:00 AM ET
Data refreshes hourly during market hours. Next update: 1:00 AM
Data refreshes hourly during market hours. Next update: 1:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is URGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Jason Drew Smith
SELL
7479 shares
2026-02-03
Mark Schoenberg
SELL
7373 shares
2026-02-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 61 BUY |
Advanced URGN Option Strategies
Professional options setups generated by AI based on today's URGN price and gamma walls.
